Literature DB >> 16724248

Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing.

Vardit Kram1, Tamar Peretz, Michal Sagi.   

Abstract

Using a specially constructed questionnaire, the effect of BRCA test results for the Jewish founder mutations and genetic counseling on women's attitudes towards and acceptance of preventive surgeries was evaluated. The subjects consisted of 99 women 43% of whom were found to be carriers as opposed to 57%--non-carriers. After learning of their genetic status, 94% of the carriers and 28% of the non-carriers declared having positively considered the option of preventive oophorectomy. However, only about 25% of the carriers and 4.5% of the non-carriers had positively considered the option of preventive mastectomy. In practice, 78% of the carriers and 18% of the non-carriers who proved to be eligible for these procedures underwent preventive oophorectomy compared with 19% of carriers and 1.8% of non-carriers who underwent preventive mastectomy. Almost all carriers, as well as a majority of the non-carriers, who finally opted for the preventive surgeries did so after learning the result of their genetic test. The different attitudes toward the two surgeries were found to be based on varied beliefs regarding the two procedures. Preventive oophorectomy was perceived as being more acceptable to women than preventive mastectomy both from an attitudinal as well as practical aspect. These differences may be the result of cultural factors, of women's trust in the ability of screening tests to prevent morbidity and/or mortality, of the effect of the surgeries on body image and of different counseling protocols.

Entities:  

Mesh:

Year:  2006        PMID: 16724248     DOI: 10.1007/s10689-006-0002-z

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  42 in total

1.  Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.

Authors:  Jeffrey R Botkin; Ken R Smith; Robert T Croyle; Bonnie J Baty; Jean E Wylie; Debra Dutson; Anna Chan; Heidi A Hamann; Caryn Lerman; Jamie McDonald; Vickie Venne; John H Ward; Elaine Lyon
Journal:  Am J Med Genet A       Date:  2003-04-30       Impact factor: 2.802

2.  What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination.

Authors:  E T Matloff; H Shappell; K Brierley; B A Bernhardt; W McKinnon; B N Peshkin
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

Review 3.  Clinical options for women at high risk for breast cancer.

Authors:  L C Hartmann; T A Sellers; D J Schaid; S Nayfield; C S Grant; J A Bjoraker; J Woods; F Couch
Journal:  Surg Clin North Am       Date:  1999-10       Impact factor: 2.741

4.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

5.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

6.  Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.

Authors:  C Lerman; C Hughes; R T Croyle; D Main; C Durham; C Snyder; A Bonney; J F Lynch; S A Narod; H T Lynch
Journal:  Prev Med       Date:  2000-07       Impact factor: 4.018

7.  Clinical follow-up after bilateral risk reducing ('prophylactic') mastectomy: mental health and body image outcomes.

Authors:  P Hopwood; A Lee; A Shenton; A Baildam; A Brain; F Lalloo; G Evans; A Howell
Journal:  Psychooncology       Date:  2000 Nov-Dec       Impact factor: 3.894

8.  Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.

Authors:  Lauren Scheuer; Noah Kauff; Mark Robson; Bridget Kelly; Richard Barakat; Jaya Satagopan; Nathan Ellis; Martee Hensley; Jeff Boyd; Patrick Borgen; Larry Norton; Kenneth Offit
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

9.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

10.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.

Authors:  J P Struewing; D Abeliovich; T Peretz; N Avishai; M M Kaback; F S Collins; L C Brody
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

View more
  10 in total

1.  Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.

Authors:  Mary S Beattie; Beth Crawford; Feng Lin; Eric Vittinghoff; John Ziegler
Journal:  Genet Test Mol Biomarkers       Date:  2009-02

2.  Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation.

Authors:  Dongwon Kim; Eunyoung Kang; Euijun Hwang; Young Sun; Yoonsun Hwang; Cha Kyong Yom; Kidong Kim; Jae Hong No; Yong-Beom Kim; Sung-Won Kim
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

3.  Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?

Authors:  Mark H Greene; Phuong L Mai; Peter E Schwartz
Journal:  Am J Obstet Gynecol       Date:  2010-07-08       Impact factor: 8.661

Review 4.  New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy.

Authors:  Suzanne M Miller; Pagona Roussi; Mary B Daly; John Scarpato
Journal:  Clin Cancer Res       Date:  2010-09-09       Impact factor: 12.531

5.  The process of deciding about prophylactic surgery for breast and ovarian cancer: Patient questions, uncertainties, and communication.

Authors:  Robert Klitzman; Wendy Chung
Journal:  Am J Med Genet A       Date:  2010-01       Impact factor: 2.802

6.  Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers.

Authors:  Lee Galmor; Rinat Bernstein-Molho; Miri Sklair-Levy; Dana Madoursky-Feldman; Dov Zippel; Yael Laitman; Eitan Friedman
Journal:  Breast Cancer Res Treat       Date:  2020-09-30       Impact factor: 4.872

Review 7.  Cell Origins of High-Grade Serous Ovarian Cancer.

Authors:  Jaeyeon Kim; Eun Young Park; Olga Kim; Jeanne M Schilder; Donna M Coffey; Chi-Heum Cho; Robert C Bast
Journal:  Cancers (Basel)       Date:  2018-11-12       Impact factor: 6.639

8.  Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis.

Authors:  Ido Laskov; Dan Grisaru; Nadav Michaan; Moshe Leshno; Yoni Cohen; Tamar Safra; Shira Peleg-Hasson
Journal:  Reprod Biol Endocrinol       Date:  2021-10-08       Impact factor: 5.211

9.  Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk-reducing surgeries in BRCA mutation carriers.

Authors:  Mahtab Vasigh; Bita Eslami; Ahmad Elahi; Ahmad Kaviani; Reza Shirkoohi; Keivan Majidzadeh; Newsha Nazarian; Ramesh Omranipour
Journal:  Mol Genet Genomic Med       Date:  2022-01-12       Impact factor: 2.183

10.  Management of the asymptomatic BRCA mutation carrier.

Authors:  Paige Teller; Rita K Kramer
Journal:  Appl Clin Genet       Date:  2010-11-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.